Phathom Pharmaceuticals Completes Enrollment for Phase 2 EoE Trial
PHAT sits 40% above its 52-week low of $7.61.
Summary
Phathom Pharmaceuticals announced the completion of enrollment for its Phase 2 clinical trial evaluating VOQUEZNA® for eosinophilic esophagitis (EoE) in adults, with topline results expected in Q4 2026.
Key Events · Product Development and Regulatory · PHAT
-
Phase 2 Enrollment Completed
Phathom Pharmaceuticals has completed enrolling 95 patients across 41 U.S. sites for its Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA® (vonoprazan) for eosinophilic esophagitis (EoE) in adults.
-
Topline Results Anticipated
The company expects to report topline results from the pHalcon-EoE-201 study in the fourth quarter of 2026.
-
Potential for Regulatory Exclusivity
Positive Phase 2 results could lead to discussions with the FDA regarding future development plans, including pediatric evaluation, which might extend regulatory exclusivity for VOQUEZNA®.
Analysis · PHAT · Life Sciences
The completion of enrollment in this Phase 2 trial is a crucial step in the development of VOQUEZNA® for a new indication, eosinophilic esophagitis. This milestone de-risks the trial timeline and brings the company closer to a significant data readout in Q4 2026, which could be a major value driver if positive.
At the time of this filing, PHAT was trading at $10.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $852.6M. The 52-week trading range was $7.61 to $18.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.